{"id":"W1991064094","doi":"10.1007/s10637-010-9408-4","title":"A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Sorafenib; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Clinical endpoint; Internal medicine; Oncology; Surgery; Phases of clinical research; Clinical trial; Chemotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002833671,0.0015708,0.002693987,0.0004930369,0.0006540555,0.001091217,0.0008866705,0.001396256,0.004330026],"category_scores_gemma":[0.002107863,0.0005098826,0.001644234,0.0004061811,0.001010514,0.0009995264,0.0006715638,0.004088081,0.0007262782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001032709,"about_ca_system_score_gemma":0.002196291,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001302149,"about_ca_topic_score_gemma":0.002701639,"domain_scores_codex":[0.9992229,0.0004763158,0.00001960465,0.0001026888,0.00005684491,0.0001216158],"domain_scores_gemma":[0.9982173,0.0003438111,0.0002033723,0.0001402983,0.00008441258,0.001010803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7696248,0.03879444,0.007842019,0.0008819663,0.002016834,0.0003782269,0.0003395806,0.003354161,0.01911774,0.0006150457,0.01302,0.1440151],"study_design_scores_gemma":[0.8505197,0.1353879,0.008335232,0.00002360222,0.0003785406,0.0002796304,0.00006251864,0.001154179,0.001260321,0.0003448517,0.002224043,0.00002956097],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9902872,0.002186493,0.0004868018,0.0016379,0.0002190604,0.001966073,0.001534727,0.0000851699,0.001596472],"genre_scores_gemma":[0.982081,0.00208074,0.003025442,0.001984754,0.0003998995,0.002794288,0.004107604,0.0000601386,0.003466092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004330026,"threshold_uncertainty_score":0.01498604,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04450204486330388,"score_gpt":0.3536828405025805,"score_spread":0.3091807956392766,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}